RESEARCH PEPTIDE FUNDAMENTALS / FAQ
Straight Answers From the Research Record
Direct, citation-anchored answers to the questions readers most often bring to these five research peptides — no hedging, no dosing advice.
What does BPC-157 do in the body?
In animal models, BPC-157 is studied mainly for its proposed effect on tissue repair — accelerating healing of tendon, ligament, and gastric-lining injuries, largely through a pro-angiogenic mechanism involving the VEGFR2 receptor and downstream nitric-oxide signaling [4]. It also modulates the FAK-paxillin pathway linked to cell migration into injury sites and, in one review, is described as a brain-gut-axis mediator affecting serotonergic and dopaminergic signaling [7]. Almost all of this comes from rodent and cell-culture studies; the only human data are a two-person intravenous safety pilot that found no adverse events, which says nothing about whether the compound works in people [1].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and not classified as a hormone at all — it is a synthetic 15-amino-acid peptide fragment derived from a protein found in human gastric juice. Its proposed effects run through vascular and tissue-repair pathways (VEGFR2-driven angiogenesis) rather than the growth-hormone/IGF-1 axis [4]. One reported mechanism does touch growth-hormone signaling: in cultured tendon fibroblasts, BPC-157 was shown to increase sensitivity of the growth-hormone receptor, which is thought to contribute to tendon repair — but that is a local sensitization effect, not evidence that BPC-157 itself functions as a growth hormone.
Does BPC-157 work immediately?
There is no human trial timeline to answer that question directly — the only human study is a short intravenous safety pilot, not an efficacy trial with a measured onset [1]. In rodent tendon and gastric-ulcer studies, healing differences versus untreated animals were measured over days to weeks, not immediately after dosing [5][6]. Community reports describe perceived improvements in stiffness or pain within one to three weeks, but that is anecdotal and unverified, not a clinical timeline.
Does BPC-157 damage the liver?
No published human or animal study in this desk's citation set reports liver damage from BPC-157. The one human pilot found no measurable changes in hepatic biomarkers at intravenous doses up to 20 mg in two adults [1]. That is a reassuring but extremely small data point — it does not establish liver safety at any scale, and a 2025 review is explicit that the human safety record remains too thin to draw firm conclusions either way [2].
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), built on the first 29 amino acids of the natural human hormone with four substitutions that resist enzymatic breakdown. Its "DAC" form chemically bonds to albumin in the blood, extending its effect from minutes to days; the "no-DAC" form (Modified GRF 1-29) lacks that albumin-binding chemistry and is short-acting. It is not approved by the FDA or any regulator and is sold only as a research chemical.
Is CJC-1295 safe?
There is no completed large-scale human safety trial to answer that definitively. What exists is a handful of small pharmacology studies in healthy adults showing sustained, dose-dependent GH/IGF-1 elevation with no reported serious adverse events at the doses tested [11][12] — reassuring in a limited way, but a long way from a safety profile. The original long-acting CJC-1295 DAC development program was discontinued, and immunogenicity concerns were flagged at a 2024 FDA compounding advisory committee for this class of molecule. Sustained IGF-1 elevation also raises a mechanism-based, unresolved question about long-term cancer risk. This page does not call CJC-1295 safe or unsafe — it reports that the safety record is thin.
How much CJC-1295 should I take?
This site does not answer that question, for anyone, under any circumstance. CJC-1295 is not an approved drug, has no FDA-labeled dose, and no clinician-supervised dosing guideline exists. The human pharmacology studies cited on this desk used specific research doses — for example, single doses of 30-90 micrograms/kg in healthy adult volunteers under study conditions [11][12] — but those are trial parameters, not recommendations, and reporting them is not the same as advising anyone to replicate them.
What does the MOTS-c peptide do?
MOTS-c is a mitochondria-encoded peptide studied mainly for its role in cellular energy regulation. Its best-characterized action is activating AMPK, a central energy-sensing enzyme, by inhibiting the folate cycle, which in animal studies improves glucose uptake and insulin sensitivity, mostly in skeletal muscle [13]. A 2024 study identified casein kinase 2 as a direct binding target, showing tissue-specific effects that protected muscle from atrophy in mice [13]. The largest piece of human evidence is observational: naturally circulating MOTS-c levels were associated with mortality and cardiovascular risk in a cohort of dialysis patients [14] — again, an association with the body's own levels, not a trial of giving the peptide as treatment.
Is MOTS-c legal to buy?
MOTS-c is legal to purchase as a research chemical for laboratory use in most jurisdictions, the same status as BPC-157 and CJC-1295. It is not approved by the FDA for human use, has no approved human indication, and is treated as a prohibited substance in elite sport under anti-doping frameworks covering metabolic modulators. "Legal to buy for research" and "appropriate to use in a person" are not the same thing, and this site does not advise on the latter.
What is PT-141 used for?
PT-141 (bremelanotide) is FDA-approved for exactly one indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, dosed as an as-needed subcutaneous injection [20][22]. Two Phase 3 trials in 1,267 women found it significantly improved sexual desire and reduced related distress versus placebo over 24 weeks [20]. Any other use — in men, in postmenopausal women, or for general sexual enhancement — is off-label and was not the population studied in the approval trials.
What is tirzepatide used for?
Tirzepatide is FDA-approved for type 2 diabetes, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. In its largest weight-management trial, participants lost a mean of up to 20.9% of body weight over 72 weeks at the highest dose versus 3.1% with placebo [26], and in a head-to-head trial it outperformed the prior single-receptor GLP-1 standard, -20.2% versus -13.7% [23].
How does tirzepatide work?
Tirzepatide activates two hormone receptors at once — GIP and GLP-1 — enhancing glucose-dependent insulin release, suppressing glucagon, slowing gastric emptying, and reducing appetite through action on hypothalamic and brainstem circuits. The dual-receptor design is the reason it's called a "twincretin," and the clearest evidence it adds something beyond single-receptor GLP-1 agonism is a head-to-head trial where it produced significantly greater weight loss than a GLP-1-only comparator [23].